Post-Exposure Prophylaxis for Blood Exposure
Immediately wash wounds with soap and water or flush mucous membranes with water, then rapidly test the source patient for HBsAg, anti-HCV, and HIV antibody (using rapid testing when available), and initiate pathogen-specific prophylaxis within hours based on exposure risk and the exposed person's immune status. 1
Immediate Wound Care
First-line management requires:
- Wash wounds and skin with soap and water
- Flush mucous membranes with water
- Do NOT squeeze or manipulate the wound 1
Risk Assessment Framework
Evaluate two critical factors:
Type of fluid:
- Blood or visibly bloody fluid (highest risk)
- Other potentially infectious fluids or tissue
- Concentrated virus
Type of exposure:
- Percutaneous injury (needlestick, cut)
- Mucous membrane exposure
- Nonintact skin exposure
- Bites resulting in blood exposure 1
Source Patient Testing
Test the source immediately for:
- HBsAg (Hepatitis B surface antigen)
- Anti-HCV (Hepatitis C antibody)
- HIV antibody (consider rapid testing for faster results)
Critical caveat: Do NOT test discarded needles or syringes for virus contamination—this is unreliable and wastes time 1
Pathogen-Specific Prophylaxis
HIV Post-Exposure Prophylaxis
Initiate antiretroviral PEP as soon as possible, ideally within 2 hours and no later than 72 hours after exposure 2, 3
Basic regimen (2001 guidelines):
- Zidovudine (ZDV/AZT) 600 mg daily in 2-3 divided doses PLUS
- Lamivudine (3TC) 150 mg twice daily
- Available as combination product (Combivir) 1
Duration: 28 days (4 weeks) 2, 3
Important considerations:
- Start with a 5-7 day starter pack if outpatient 2
- Nevirapine should NEVER be used due to severe hepatic and cutaneous toxicity 2
- Efavirenz should be avoided if pregnancy is known or suspected due to teratogenicity 2
- Consultation with infectious disease specialists is strongly recommended for regimen selection 2
- Reassess within 72 hours for adherence and toxicity 2
Monitoring:
- Baseline: Complete blood count, renal function, hepatic function, pregnancy test (women)
- Follow-up labs at 2 weeks: CBC, renal and hepatic function
- HIV antibody testing: baseline, 6 weeks, 3 months, and 6 months 2, 4
Hepatitis B Post-Exposure Prophylaxis
Management depends entirely on the exposed person's vaccination and immune status:
For unvaccinated persons exposed to HBsAg-positive source:
- Hepatitis B vaccine series (initiate immediately)
- PLUS Hepatitis B immune globulin (HBIG) within 24 hours 1, 5
For vaccinated persons with known adequate response (anti-HBs ≥10 mIU/mL):
- No treatment needed
For vaccinated persons with unknown or inadequate response:
- Test anti-HBs levels
- Give HBIG if levels inadequate and source is HBsAg-positive
- Consider booster dose of vaccine 1
Follow-up testing:
- Check anti-HBs 1-2 months after last vaccine dose
- Note: Cannot accurately assess vaccine response if HBIG given within previous 3-4 months 1
Hepatitis C Post-Exposure Management
No prophylaxis is available or recommended for HCV 1, 5
Instead, implement surveillance strategy:
- Baseline testing: anti-HCV and ALT
- Follow-up at 4-6 months: anti-HCV and ALT
- For earlier diagnosis: HCV RNA at 4-6 weeks 1
- Confirm repeatedly reactive anti-HCV enzyme immunoassays with supplemental tests 1
If acute HCV infection develops:
- Interferon-alpha monotherapy can prevent chronification in most patients 5
- Early treatment is key
Tetanus Prophylaxis
Assess tetanus immunization status:
- If last tetanus toxoid >5 years ago: Give Td (or Tdap if indicated)
- For contaminated wounds with uncertain/incomplete vaccination: Give tetanus toxoid AND tetanus immune globulin (TIG) 2
- Use separate syringes and anatomic sites when giving toxoid and TIG concurrently 2
Critical Timing Considerations
Time is tissue—act fast:
- HIV PEP: Most effective within 2 hours, must start within 72 hours 2, 3
- Hepatitis B HBIG: Within 24 hours 5
- Tetanus: Can be given regardless of delay, but earlier is better 4
Common Pitfalls to Avoid
- Don't wait for source patient test results to start PEP—initiate based on risk assessment and adjust later 1
- Don't use nevirapine in HIV PEP regimens—serious toxicity risk 2
- Don't test discarded needles—unreliable and delays care 1
- Don't forget pregnancy testing before efavirenz—teratogenic 2
- Don't assume vaccinated = immune for HBV—verify anti-HBs response 1
Baseline Testing of Exposed Person
Before or immediately after starting PEP, obtain:
- HIV antibody
- HBsAg and anti-HBs (if HBV vaccination status uncertain)
- Anti-HCV
- Complete blood count
- Renal and hepatic function tests
- Pregnancy test (women of childbearing age) 2, 4
Special Populations
Pregnancy: